Influenza Vaccines – Your 2016 Guide to Developments and Sales Potentials Do you want to explore the future of vaccines against the influenza virus? If so, Visiongain’s new report shows you trends, R&D, sales results, opportunities and revenue forecasts.
Avoid missing out. With our research and analysis you assess companies, technologies and products, benefiting your reputation for commercial insight.
Read on to explore the flu shots industry and see what revenue its market could generate in future.
Sales prospects of human flu preventions – our study shows you what is possible Our new study gives revenue predictions at overall world, submarket, product and national levels. You gain discussions and expert opinion on vaccines protecting against influenza: • Influenza vaccine revenues to 2026 – discover the overall potential of that market worldwide, seeing commercial opportunities and possibilities • 2 submarkets’ revenues to 2026 – explore that industry’s segments at world level, finding the most lucrative and promising technologies and trends • 6 revenue forecasts covering leading vaccine brands to 2026 – see how those anti-flu agents can compete and succeed, discovering their sales potentials • 11 leading countries’ revenue forecasts to 2026 – investigate countries in the Americas, Europe and Asia, assessing prospects for influenza market expansion • Analysis of leading companies and R&D pipelines for that preventive medicine – assess potentials of companies, seeing how they can compete and succeed • Assessment of what stimulates and restrains that important healthcare market – analyse challenges, strengths and views, seeing how you can gain.
Forecasting of that world market, showing what is possible for those prophylactic medicines In our 138 page report you receive 32 tables, 32 charts and an interview with a vaccine producer. Besides giving revenue predictions, our new analysis shows you recent results, business news, sales growth rates, market shares and R&D trends.
First our study gives revenue forecasts to 2026 for two influenza submarkets: • Trivalent vaccines • Quadrivalent vaccines.
With our report you investigate influenza vaccine development, manufacturing and selling. You also explore potential shifts in market shares from 2016 to 2026. See what leading companies do, assessing that industry’s potential.
Product forecasts – assess sales potentials of leading brands Our new analysis also shows you predictions for leading flu vaccines, giving six revenue forecasts to 2026: • Fluzone/Vaxigrip • Afluria/Fluvax • Fluarix/FluLaval • FluMist/Fluenz • Fluvirin/Flucelvax • FluBlok.
With our investigation you assess business potentials for leading influenza vaccines. You also explore research and development. Discover what is possible from 2016, then, benefiting your influence and reputation for commercial insight.
National markets for influenza vaccine sales – what does the future hold? Our study shows you prospects for influenza vaccine revenues in developed and developing countries. There see individual forecasts to 2026 for 11 countries: • United States • Japan • Germany, France, United Kingdom, Italy and Spain (the EU5 group) • Brazil, Russia, India and China (the BRIC group).
With our analysis you investigate countries with highest revenues, demand and potential sales growth. Explore progress, needs and opportunities, seeing how you can gain.
Forces affecting developers, producers and sellers of those healthcare products Our report explains issues, trends, events and R&D from 2016, including these forces: • Paediatric and adult influenza vaccines – present and future developments • Advances in research and development, including vaccine delivery technology – assess innovations, progress and opportunities • Deals in that industry, including the creation of Seqirus in July 2015 • Antigenic drift and shift – overcoming viral challenges to protect populations • Seasonal influenza epidemics and pandemic outbreaks giving high demand.
Also explore the effects of these influences: • Governments and international organisations’ roles in flu vaccination • Supply and demand, including effects of healthcare providers and payers’ policies • US healthcare reforms – benefits for vaccine sales • Strengths, weaknesses, opportunities and threats, as well as social, technological, economic and political forces – examine what influences that industry • Potential for universal flu vaccine to transform the market – see what is possible.
Worldwide revenues of influenza vaccines will reach $6.4 billion in 2018, our study predicts. Sales will rise from 2016 to 2026 as technological advances and rising demand give growth opportunities. With our analysis you see what the future holds and how you can benefit.
Influenza vaccines – who are the top companies? From 2016, large pharmaceutical companies and other biopharma specialists can prosper in that important healthcare market. Discover how, seeing organisations’ potentials.
In particular our study explores these industry leaders: • Sanofi Pasteur • GSK • Novartis • AstraZeneca • CSL and Seqirus • Protein Sciences Corporation.
Gain predictions for influenza vaccines, getting information to help you stay ahead With our independent study you assess products, companies, progress and potentials. Explore commercial opportunities and technological advances. Discover what is possible.
Having that information means you are less likely to fall behind in knowledge or miss opportunity. Through your choice now, find how to save time and effort, also benefiting your plans, decisions, presentations, proposals and influence.
Try our new study. That investigation shows you data, trends, opportunities and forecasts for that expanding vaccine market. So avoid missing out – please get our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Global Influenza Vaccine Market Overview 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analytical Study 1.5 Who is This Report For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQ) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2. Introduction to the World Influenza Vaccines Market 2.1 What is Influenza and How Serious is it to Health Worldwide? 2.2 What is the Social and Economic Burden? 2.3 The Influenza Virus 2.3.1 Antigenic Drift 2.3.2 Antigenic Shift 2.4 An Epidemic or a Pandemic Outbreak? 2.4.1 Seasonal Influenza Epidemic 2.4.2 Pandemic Influenza 2.5 Key Influencers of the Influenza Vaccine Market 2.5.1 Governments and International Organisations 2.5.1.1 The World Health Organization (WHO) 2.5.1.2 Governmental Influence 2.5.2 Leading Manufacturers 2.5.2.1 Sanofi Pasteur 2.5.2.2 GSK 2.5.2.3 Novartis 2.5.2.4 AstraZeneca
3. Influenza Vaccine World Market Outlook, 2016-2026 3.1 The World Influenza Market Performance 2014 3.1.1 Growing Elderly Population 3.1.2 Paediatric Influenza Vaccines – High Demand 3.1.3 Emerging Markets 3.2 The World Influenza Market Revenue Forecast, 2015-2026 3.3 The World Influenza Market: Industry Trends, 2016-2026 3.3.1 Demand Driven Trends 3.3.2 Supply 3.3.3 Funding Trends 3.3.4 Protecting the Workforce of an Economy
5. Leading Influenza Vaccines: Revenue Predictions, 2016-2026 5.1 Fluzone/Vaxigrip (IIV4) - Sales Forecasting and Discussion 2015-2026 5.2 Afluria/Fluvax (IIV3) - Sales Forecasting and Discussion 2015-2026 5.3 Fluarix/FluLaval - Sales Forecasting and Discussion 2015-2026 5.4 FluMist/Fluenz (LAIV4) - Sales Forecasting and Discussion 2015-2026 5.5 Fluvirin (IIV3) / Flucelvax (ccIIV3) - Sales Forecasting and Discussion 2015-2026 5.6 FluBlok (RIV3) - Sales Forecasting and Discussion 2015-2026 5.7 Other Vaccines: Sales Forecasting and Discussion 2015-2026
6. Influenza Vaccines in Leading Developed Markets, 2016-2026 6.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026 6.1.1 Influenza Vaccine: Leading Developed Markets 6.2 The US Vaccine Market: 2016-2026 6.2.1 The US Vaccine Market: 2015 6.2.2 The US Vaccine Market Forecast: 2015-2026 6.2.3 Obama Healthcare Reform - Benefits for Vaccine Sales 6.3 The Japanese Influenza Vaccine Market 2016-2026 6.3.1 The Japanese Vaccine Market: 2015 6.3.2 The Japanese Vaccine Market Forecast: 2015-2026 6.3.3 Filing the Vaccine Gap 6.4 The United Kingdom Influenza Vaccine Market 2016-2026 6.4.1 The UK Vaccine Market: 2015 6.4.2 The UK Vaccine Market: 2015-2026 6.5 The German Influenza Vaccine Market: 2016-2026 6.5.1 The German Vaccine Market: 2015 6.5.2 The German Vaccine Market Forecast: 2015-2026 6.6 The French Influenza Vaccine Market 2016-2026 6.6.1 The French Vaccine Market: 2015 6.6.2 The French Vaccine Market Forecast: 2015-2026 6.6.3 French Healthcare System – Events, Policies and Effects 6.7 The Italian Influenza Vaccine Market: 2016-2026 6.7.1 The Italian Vaccine Market: 2015 6.7.2 The Italian Vaccine Market Forecast: 2015-2026 6.7.3 Uncertain Foundation – Challenges in Public Healthcare 6.8 The Spanish Influenza Vaccine Market 2016-2026 6.8.1 The Spanish Vaccine Market: 2015 6.8.2 The Spanish Vaccine Market Forecast: 2015-2026 6.8.3 District Rules – Economic Challenges
7. Influenza Vaccines in Leading Emerging Markets, 2016-2026 7.1 Influenza Vaccines: Leading Markets, 2014, 2020, 2026 7.1.1 Influenza Vaccine: Leading Emerging National Markets 7.2 The Chinese Influenza Vaccine Market: 2016-2026 7.2.1 The Chinese Influenza Vaccine Market: 2015 7.2.2 The Chinese Influenza Vaccine Market Forecast: 2015-2026 7.2.3 High National Demand for Influenza Vaccines 7.3 The Indian Influenza Vaccine Market: 2016-2026 7.3.1 The Indian Vaccine Market: 2015 7.3.2 The Indian Influenza Vaccine Market Forecast: 2015-2026 7.3.3 Complications of Influenza Vaccines – How Much Progress Possible? 7.4 The Brazilian Influenza Vaccine Market: 2016-2026 7.4.1 The Brazilian Vaccine Market: 2015 7.4.2 The Brazilian Vaccine Market Forecast: 2015-2026 7.5 The Russian Vaccine Market: 2016-2026 7.5.1 The Russian Vaccine Market: 2015 7.5.2 The Russian Vaccine Market Forecast: 2015-2026 7.5.3 Power of the State
9. Qualitative Analysis of the World Influenza Vaccines Industry and Market, 2016-2026 9.1 SWOT Analysis of the World Influenza Vaccines Industry and Market, 2016 9.1.1 Strengths 9.1.1.1 Ageing Population 9.1.1.2 Influenza Prevention is Crucial 9.1.1.3 Sales Growth in Emerging National Markets 9.1.1.4 Rising Awareness of the Disease 9.1.2 Weaknesses 9.1.2.1 Supply Chain Costs 9.1.2.2 Time Pressure 9.1.2.3 Barriers to Market Entry 9.1.3 Opportunities 9.1.3.1 Strong Research and Development Pipeline 9.1.3.2 Vaccine Delivery – Innovations and Opportunities for Improvements 9.1.3.3 Universal Flu Vaccine 9.1.3.4 Adult Vaccines – High Need 9.1.4 Threats 9.1.4.1 Productivity Gap 9.2 STEP Analysis of the World Influenza Vaccines Industry and Market, 2016 9.2.1 Social Factors 9.2.1.1 Creating a Healthier Society 9.2.1.2 Public Fears of Side-Effects 9.2.2 Technological Forces 9.2.2.1 Advancements in Vaccine Technology 9.2.3 Economic Factors 9.2.3.1 Cost and Time Restraints 9.2.3.2 Emerging Markets Create Demand 9.2.4 Political Factors 9.2.4.1 Influence of Governments
10. Research Interview 10.1 Interview with BiondVax Pharmaceuticals, 2013 10.1.1 Progress of BiondVax’s Candidate Vaccine 10.1.2 Trialling the Vaccine as a Primer 10.1.3 Assays for Universal Vaccine Effectiveness 10.1.4 Key Differentiators for BiondVax’s Candidate
11. Conclusions 11.1 Prevention of Influenza by Use of Flu Shots Rises in Importance 11.2 Japan as a Rising Consumer in the World Influenza Vaccine Market 11.3 Brazil and India Show Robust Growth 11.4 Emergence of a Universal Flu Vaccine 11.5 The US to Retain its Dominance 11.6 Concluding Remarks
List of Tables Table 1.1 Selected National Vaccines Markets: Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 Table 3.1 Overall World Influenza Vaccine Market: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026 Table 4.1 Influenza Vaccines Sub-Markets: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026 Table 4.2 The Trivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026 Table 4.3 The Quadrivalent Influenza Vaccines Submarket: Revenue Forecast ($m), Annual Growth (%), CAGR (%), 2015-2026 Table 5.1 Leading Influenza Vaccines: Revenues ($m), 2014 Table 5.2 Fluzone/Vaxigrip: Revenue ($m), 2012-2014 Table 5.3 Fluzone/Vaxigrip: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.4 Afluria/Fluvax: Revenue ($m), 2013-2014 Table 5.5 Afluria/Fluvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.6 Fluarix/FluLaval: Revenue ($m), 2012-2014 Table 5.7 Fluarix/FluLaval: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.8 FluMist/Fluenz: Revenue ($m), 2012-2014 Table 5.9 FluMist/Fluenz: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.10 Fluvirin/Flucelvax Revenue ($m), 2013-2014 Table 5.11 Fluvirin/Flucelvax: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.12 FluBlok Revenue ($m), 2013-2014 Table 5.13 FluBlok: Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 5.14 Other Influenza Vaccines Forecast: ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 6.1 Influenza Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 Table 6.2 The US Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 6.3 The Japanese Influenza Vaccine Revenue Forecast ($m), Annual Growth ($m), CAGR (%), 2015-2026 Table 6.4 The UK Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 6.5 The German Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 6.6 The French Human Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 6.7 The Italian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 6.8 The Spanish Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.1 Human Vaccines Market Revenues ($m) and Market Shares (%) by Leading Country, 2014, 2020 and 2026 Table 7.2 The Chinese Human Vaccines Forecast ($bn), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.3 The Indian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.4 The Brazilian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 7.5 The Russian Influenza Vaccines Forecast ($m), Annual Growth (%) and CAGR (%), 2015-2026 Table 8.1 Seasonal Influenza Vaccines in Development, 2015 Table 8.2 Universal Influenza Vaccines in Development, 2015
List of Figures Figure 1.1 Influenza Vaccines Market Segmentation Figure 3.1 Influenza Vaccines Market Shares (%), 2014 Figure 3.2 Growth in the Uptake of Influenza Vaccine, 1990-2015 Figure 3.3 Influenza Vaccines: Segmentation by Age (%), 2014 Figure 3.4 Time of Last Influenza Shot by Age, 2015 Figure 3.5 Influenza Vaccines: Market Share by Geographical Segmentation, 2015 Figure 3.6 World Influenza Vaccines Market: Drivers and Restraints, 2016-2026 Figure 4.1 Influenza Vaccines: Main Submarket Segmentation (%), 2014 Figure 4.2 Influenza Vaccines: Submarkets Shift in Market Share (%), 2014-2026 Figure 5.1 Fluzone/Vaxigrip: Revenue Forecast ($m), 2015-2026 Figure 5.2 Afluria/Fluvax: Revenue Forecast ($m), 2015-2026 Figure 5.3 Fluarix/FluLaval: Revenue Forecast ($m), 2015-2026 Figure 5.4 FluMist/Fluenz: Revenue Forecast ($m), 2015-2026 Figure 5.5 Fluvirin/Flucelvax: Revenue Forecast
Advisory Committee for Immunization Practices Astellas Pharmaceuticals AstraZeneca Bharat Immunologicals and Biologicals Corporation Limited Binnopharm bioCSL BioManguinhos/Oswaldo Cruz Foundation BiondVax BiondVax Bionor Brazilian Ministry of Health Butantan Institute Center for Biologics Evaluation and Research Centre for Disease Control and Prevention China National Biotech Group China’s National Regulatory Authority Chinese Food and Drug Administration CSL CureVac Daiichi Sankyo Dynavax Flanders Institute Food and Drug Administration (FDA) FORT Fresenius Pharmaceuticals Gamma Vaccines Gavi Alliance GlaxoSmithKline (GSK) Global Influenza Programme Grippol Health Service Bureau, Japan Immune Targeting Systems Indian Association of Paediatrics Janssen Pharmaceuticals Jenner Institute, University of Oxford Johnson & Johnson Krka Pharmaceuticals Medicago Medicare MedImmune Merck MSD Pharmaceuticals National Health Service, UK Novartis Organisation for Economic Co-operation and Development Panacea Biotech Partnership for Influenza Vaccine Introduction Petrovax Pfizer Protein Sciences Corporation Sanofi Pasteur Seqirus Servizio Sanitario Nationale Shionogi Pharmaceuticals Sistema Unico de Saude SmithKline Beecham Takeda Pharmaceuticals Terumo Pharmaceuticals The Ministry of Health, Labour and Welfare, Japan The Scripps Research Institute Ultriks US Department of Health and Human Services VaxInnate WHO Strategic Advisory Group of Experts World Health Organization (WHO)
Download sample pages
Complete the form below to download your free sample pages for Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026
Download sample pages
Complete the form below to download your free sample pages for Influenza Vaccine Revenue Forecasts and R&D Outlook 2016-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
